PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Internal Medicine, Department of Cardiology, NYU Winthrop Hospital, Mineola, NY, USA.\', \'From the New York University Grossman School of Medicine, Department of Medicine, New York, NY, USA.\', \'Applied Therapeutics, New York, NY, USA.\', \'Applied Therapeutics, New York, NY, USA. Electronic address: rperfetti@appliedtherapeutics.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1871-4021(21)00348-910.1016/j.dsx.2021.102328
?:doi
?:hasPublicationType
?:journal
  • Diabetes & metabolic syndrome
is ?:pmid of
?:pmid
?:pmid
  • 34752935
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis.
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34752935>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34752935>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all